Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2++ metastatic breast cancer with letrozole alone or in combination with lapatinib

Author: Sherrill Beth   Sherif Bintu   Amonkar Mayur M.   Maltzman Julie   O’Rourke Lisa   Johnston Stephen  

Publisher: Informa Healthcare

ISSN: 1473-4877

Source: Current Medical Research and Opinion, Vol.27, Iss.12, 2011-12, pp. : 2245-2252

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract